• Ashley EA, Krudsood S, Phaiphun L et al. (2004) Randomized, controlled dose-optimization studies of dihydroartemisinin–piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. The Journal of Infectious Diseases 190, 17731782.
  • Ashley EA, McGready R, Hutagalung R et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin–piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clinical Infectious Diseases 41, 425432.
  • Brockman A, Paul REL, Anderson T et al. (1999) Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. The American Journal of Tropical Medicine and Hygiene 60, 1421.
  • Chatterjee P (2005) Cambodia's fight against malaria. The Lancet 366, 191192.
  • Denis MB, Davis TM, Hewitt S et al. (2002) Efficacy and safety of dihydroartemisinin–piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clinical Infectious Diseases 35, 14691476.
  • Ezedinachi EN, Ekanem OJ, Chukwuani CM et al. (1999) Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum. The American Journal of Tropical Medicine and Hygiene 61, 114119.
  • Karunajeewa H, Lim C, Hung TY et al. (2004) Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. British Journal of Clinical Pharmacology 57, 9399.
  • Krudsood S, Looareesuwan S, Silachamroon U et al. (2002) Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. The American Journal of Tropical Medicine and Hygiene 67, 465472.
  • Ter Kuile FO, Nosten F, Luxemburger C et al. (1995) Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bulletin of the World Health Organization 73, 631642.
  • Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 17, 873890. Available at:, accessed in July 2006.
  • Nosten F, Van Vugt M, Price R et al. (2000) Effects of artesunate–mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297302.
  • Piaggio G, Elbourne DR, Altman DG et al. (2006) Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 295, 11521160.
  • Price RN, Uhlemann AC, Brockman A et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438447.
  • Smithuis F, Kyaw MK, Phe O et al. (2006) Efficacy and effectiveness of dihydroartemisinin–piperaquine versus artesunate–mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006 367, 20752085.
  • Tran TH, Dolecek C, Phan PM et al. (2004) Dihydroartemisinin–piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363, 1822.
  • WHO (2003) Position of WHO's Roll Back Malaria Department on malaria treatment policy. Available at: Accessed in June 2005.
  • WHO (2006) Guidelines for the Treatment of Malaria. (WHO/HTM/MAL/2006.1108) WHO. Available at:, accessed in June 2006.
  • Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ & White NJ (2004) Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. The American Journal of Tropical Medicine and Hygiene 71 (Suppl. 2), 179186.